Scil Biomedical (Martinsried, Germany), a developer, manufacturer and marketer of protein based pharmaceuticals and devices, has promoted Thomas Keller to the position of CEO. Mr Keller, who joined the company in January, previously served as vice-president of marketing and sales. He replaces Ulrich Martin, who will continue to act as a consultant.
PEOPLE - Scil Biomedical (Germany) makes promotion:
Scil Biomedical (Martinsried, Germany), a developer, manufacturer and marketer of protein based pharmaceuticals and devices, has promoted Thomas Keller to the position of CEO. Mr Keller, who joined the company in January, previously served as vice-president of marketing and sales. He replaces Ulrich Martin, who will continue to act as a consultant.
More from Archive
More from Medtech Insight
Fresh off an IPO, spinal implant maker Carlsmed is preparing to launch a new cervical fusion application for its aprevo tech. Medtech Insight has two perspectives on these recent moves: CEO Mike Cordonnier and the doctor who performed the first spinal fusion using the technology.
Daye is launching an at-home reproductive hormone testing service in the UK, utilizing a painless upper arm blood collection method. The product’s UKAS lab accreditation helps build credibility with healthcare providers.
BD raised its adjusted earnings per share guidance midpoint by $0.18 to a range of $14.30 to $14.45, representing growth of about 9.4% at the midpoint – an increase of approximately 1.4% over prior guidance.